Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Inves ...

electroCore, Inc. (NASDAQ: ECOR )’s stock has awakened. On November 13, 2024, the company presented last quarter's results with revenue of $6.55 million, growing +45% year over year and just missing analyst expectations by $0.16 million. Earnings per share were -$0.31 per share, beating analysts’ expectations by $0.02Investing in high-growth opportunities across industries, employing a value investing approach that prioritizes robust business models and strategic foresight. Focusing on companies with the po ...

We add real-time buy and sell signals on these, as well as other trading opportunities which we provide in our active chat community. We look at companies with a defensible competitive advantage and the opportunity and/or business models which have the potential to generate considerable operational leverage.If you are interested in similarly small, high-growth potential stocks you could join us at our marketplace service SHU Growth Portfolio , where we maintain a portfolio and a watchlist of similar stocks. ...

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered into a definitive agreement to acquire NeuroMetrix, Inc. (“NeuroMetrix” or “NURO” ...

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place in New York City on November 21, 2024. Joshua Lev, Chief Financial Officer, will host one-on-one meetings throughout the day. To schedule a one-on-one meeting with Mr. Lev, investors are encouraged to reach out to their ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the electroCore Third Quarter 2024 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Gol ...

ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.90%. A quarter ago, it was expected that this company would post a loss of $0.39 per share when it actually produced a loss of $0.38, delivering a surprise of 2.56%.Over the last four quarters, the company has surpass ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ECOR Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _________ ...

electroCore Announces Third Quarter 2024 Financial Results Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, NJ, November 13, 2024 (GLOBE NEWSWIRE) – electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights · Eighth consecuti ...

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at 4:30 p.m. EST ROCKAWAY, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2024 financial results. Recent Highlights Eighth consecutive record quarterly revenue of $6.6 million, an increase of 4 ...